股票代码：002728 股票简称：特一药业 公告编号：2024-058 特一药业集团股份有限公司 关于参加广东辖区 2024 年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 为进一步加强与投资者的互动交流，特一药业集团股份有限公司（以下简称"公司"） 将参加由广东证监局、广东上市公司协会联合举办的"坚定信心 携手共进 助力上市公 司提升投资价值——2024广东辖区上市公司投资者关系管理月活动投资者集体接待日" 活动，现将相关事项公告如下： 本次活动将采用网络远程的方式举行 ， 投资者可登录 " 全 景 路 演 " 网 站 （http://rs.p5w.net）参与本次互动交流，活动时间为 2024 年 9 月 12 日（周四）15:30-16:30。 届时公司董事长、总经理许丹青先生，董事、董事会秘书、财务总监、副总经理陈 习良先生将在线就 2024 年半年度业绩、公司治理、发展战略、经营状况和可持续发展 等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 特一药业集团股份有限公司 董事会 202 ...

本次回购股份资金来源为公司自有资金，回购价格未超过回购方案中拟定的价格上 限 12.96 元/股（含）。本次回购符合公司回购股份方案及相关法律、法规的要求。 股票代码：002728 股票简称：特一药业 公告编号：2024-057 特一药业集团股份有限公司 关于股份回购进展情况的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特一药业集团股份有限公司（以下简称"特一药业"或"公司"）于 2024 年 6 月 11 日 召开第五届董事会第二十三次会议，审议通过了《关于回购公司股份方案的议案》，同 意公司以自有资金采取集中竞价交易方式回购公司股份，用于股权激励或员工持股计划， 本次公司回购股份的种类为公司已发行的人民币普通股（A 股）股票，回购股份的资金 总额不低于人民币 7,000 万元（含）且不超过人民币 12,000 万元（含），回购股份的价 格不超过人民币 12.96 元/股（含）。本次回购期限自公司董事会审议通过本次回购股份 方案之日起 12 个月内。具体内容详见公司刊载于巨潮资讯网的相关公告。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自 ...

Group 1: Performance Dependency on Key Product - The company's performance is significantly influenced by the main product, Zhi Ke Bao Pian, but it does not rely excessively on it. In 2023, Zhi Ke Bao Pian accounted for 41.96% of the company's total revenue [2][3]. - The gross profit margin of Zhi Ke Bao Pian, after deducting marketing expenses, reached 38.66% in 2023, indicating a strong contribution to overall profitability [2][3]. Group 2: Marketing and Brand Investment - The company has consistently invested in brand building and marketing for Zhi Ke Bao Pian, despite challenges in sales during certain years due to market restrictions [2][3]. - Marketing expenses for Zhi Ke Bao Pian have been substantial, with a peak of 14,729.20 thousand in 2023, reflecting the company's commitment to maintaining market presence [3][5]. Group 3: Future Product Development and Risk Management - To enhance core competitiveness, the company is increasing marketing efforts for potential products like Pi Fu Bing Xue Du Wan and Jiang Tang Shu Wan, which show promising market feedback [4]. - The company plans to leverage the "raw material + formulation" policy to improve product quality and reduce costs, thereby enhancing competitiveness [4]. Group 4: Organizational Changes and Market Strategy - The company is undergoing a marketing organizational transformation to adapt to changing consumer behaviors and multi-channel marketing trends, which is crucial for long-term development [5]. - As of August 2024, the company has established sales intentions with most of the 38 major chain pharmacies, indicating a strategic approach to expanding market reach [5].

特一药业集团股份有限公司（以下简称"特一药业"或"公司"）于 2024 年 6 月 11 日 召开第五届董事会第二十三次会议，审议通过了《关于回购公司股份方案的议案》，同 意公司以自有资金采取集中竞价交易方式回购公司股份，用于股权激励或员工持股计划， 本次公司回购股份的种类为公司已发行的人民币普通股（A 股）股票，回购股份的资金 总额不低于人民币 7,000 万元（含）且不超过人民币 12,000 万元（含），回购股份的价 格不超过人民币 12.96 元/股（含）。本次回购期限自公司董事会审议通过本次回购股份 方案之日起 12 个月内。具体内容详见公司刊载于巨潮资讯网的相关公告。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号—— 回购股份》的相关规定，公司应当在每个月的前三个交易日内披露截至上月末的回购进 展情况。现将公司回购公司股份的进展情况公告如下： 一、回购股份的进展情况 股票代码：002728 股票简称：特一药业 公告编号：2024-056 特一药业集团股份有限公司 关于股份回购进展情况的公告 截至 2024 年 7 月 31 日，公司通过深圳证券交易所交易系统以集中竞价 ...

股票代码：002728 股票简称：特一药业 公告编号：2024-055 特一药业集团股份有限公司 特一药业集团股份有限公司（以下简称"特一药业"或"公司"）于 2024 年 6 月 11 日 召开第五届董事会第二十三次会议，审议通过了《关于回购公司股份方案的议案》，同 意公司以自有资金采取集中竞价交易方式回购公司股份，用于股权激励或员工持股计划， 本次公司回购股份的种类为公司已发行的人民币普通股（A 股）股票，回购股份的资金 总额不低于人民币 7,000 万元（含）且不超过人民币 12,000 万元（含），回购股份的价 格不超过人民币 12.96 元/股（含）。本次回购期限自公司董事会审议通过本次回购股份 方案之日起 12 个月内。具体内容详见公司刊载于巨潮资讯网的相关公告。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号—— 回购股份》的相关规定，公司在回购股份期间，应当在回购股份占公司总股本的比例每 增加 1%的事实发生之日起三个交易日内予以披露。现将公司回购公司股份的进展情况 公告如下： 一、回购股份的进展情况 截至 2024 年 7 月 29 日，公司通过深圳证券交易所交易 ...

Financial Performance - The company's operating revenue for the reporting period was approximately ¥313.75 million, a decrease of 41.72% year-on-year, primarily due to a decline in sales of traditional Chinese medicine[98]. - Total revenue for the reporting period was ¥313,748,456.95, a decrease of 41.72% compared to ¥538,380,647.61 in the same period last year[119]. - Revenue from the pharmaceutical industry was ¥305,371,216.37, accounting for 97.33% of total revenue, down 42.35% year-on-year[119]. - Revenue from traditional Chinese medicine decreased by 72.64% to ¥83,895,259.38, with a gross profit margin of 56.86%[119]. - Revenue from chemical raw materials increased by 13.73% to ¥28,982,764.36, with a gross profit margin of 55.04%[119]. - The gross profit margin for the pharmaceutical industry was 39.71%, a decrease of 19.45% compared to the previous year[119]. - The company reported a net profit of approximately ¥2.69 million, a significant decrease of 98.23% year-on-year, indicating challenges in maintaining profitability[113]. - The company's net cash flow from operating activities was approximately -¥42.67 million, a significant decrease of 173.11% compared to the previous year, mainly due to a sharp decline in cash received from sales[98]. Cash and Cash Equivalents - The company's cash and cash equivalents at the end of the reporting period amounted to ¥63,607.60, compared to ¥52,921.64 at the beginning of the period[38]. - The total cash and cash equivalents decreased from ¥647,247,165.22 at the beginning of the period to ¥407,246,040.20 at the end of the period[38]. - Cash and cash equivalents at the end of the reporting period were ¥407,246,040.20, representing 16.91% of total assets, down 8.85% from the previous year[120]. Investments and Capital Raising - The company raised a total of RMB 274,999,916.10 from issuing 20,146,514 shares at a price of RMB 13.65 per share, with a net amount of RMB 268,891,257.70 after deducting fees[127]. - As of June 30, 2024, the company has invested a total of RMB 60,000,000.00 in projects funded by the raised capital, with no new investments during the reporting period[127]. - The company has cumulatively invested RMB 290,688,816.65 from the proceeds of convertible bonds, with RMB 21,879,797.53 invested during the reporting period[138]. - The company raised RMB 196,999,934.04 from a non-public offering of 18,040,287 shares, with a net amount of RMB 184,905,449.15 after fees[139]. - Cumulative investments from the non-public offering proceeds reached RMB 148,942,554.98, with RMB 29,601,251.00 invested during the reporting period[139]. Subsidiaries and Operations - The company has a total of 9 subsidiaries, including Taisan Xinning Pharmaceutical Co., Ltd. and Hainan Haili Pharmaceutical Co., Ltd.[28]. - The company is focused on the pharmaceutical manufacturing industry, primarily engaged in the R&D, production, and sales of traditional Chinese medicine, chemical preparations, and chemical raw materials[59]. - The company has 18 products that have passed the consistency evaluation, including cefalexin capsules and amoxicillin capsules, and holds a total of 33 invention patents, 23 design patents, and 8 utility model patents[67]. Marketing and Sales Strategy - The company is transitioning its sales model from a distributor model to a hybrid model of self-operated and distributed sales, particularly for OTC products like the core product, Zhi Ke Bao Pian[64]. - The company continues to invest in brand promotion for Zhi Ke Bao Pian, resulting in a high proportion of sales expenses relative to operating revenue[90]. - The company is collaborating with research institutions to enhance drug quality and efficacy consistency evaluations, which is expected to improve market competitiveness[67]. - The company has implemented a marketing organization restructuring to enhance long-term development[64]. Risk Management - The company has detailed its risks and response measures in the management discussion and analysis section of the report[41]. - The company faced significant risks due to recent healthcare policy reforms impacting the pharmaceutical industry[182]. - The company faces risks related to drug price reductions due to government reforms aimed at lowering medical costs, which may lead to a decline in average profit margins in the pharmaceutical industry[183]. - Environmental risks are heightened as stricter regulations under the new Environmental Protection Law may increase the company's expenditures on pollution control and lead to potential penalties for non-compliance[185]. - The company is committed to risk management strategies to navigate changes in its marketing organization effectively[166]. Environmental Compliance - The company is classified as a key pollutant discharge unit and complies with various environmental protection laws and regulations[155]. - The total wastewater discharge from Taishan Xinning Pharmaceutical Co., Ltd. was 3.285 tons per year, with CODcr levels at 0.952 tons, ammonia nitrogen at 0.00522 tons, and total nitrogen at 0.046 tons, all compliant with local standards[159]. - The company has invested significantly in environmental protection measures, continuously improving process technology to reduce resource consumption and environmental pollution[163]. - The company reported a total investment of 80,015.4 million, with 5,148.11 million already utilized, indicating a commitment to ongoing projects[165]. Stock Options and Employee Incentives - The company approved the 2021 Stock Option Incentive Plan on October 12, 2021, during the 21st meeting of the fourth board of directors[44]. - The company has completed the stock option grant registration for 4 million options at an exercise price of CNY 14.22 per share[144]. - A total of 28.10 million stock options were canceled, leaving 371.90 million options still unexercised[145]. - The stock options for the second exercise period have been approved, allowing 155.148 million options to be exercised at an adjusted price of CNY 9.23 per share[149]. Corporate Governance - The company has confirmed that it will not make retrospective adjustments or restate previous years' accounting data[34]. - The company has not reported any discrepancies between net profit and net assets under domestic and foreign accounting standards[53]. - The company held its annual general meeting on March 28, 2024, with a participation rate of 27.63%[170].

特一药业集团股份有限公司 关于第五届董事会第二十四次会议决议的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 一、董事会会议召开情况 特一药业集团股份有限公司（以下简称"公司"）第五届董事会第二十四次会议于 2024 年 7 月 25 日 09:30 在公司会议室采用现场及通讯方式召开，会议通知于 2024 年 7 月 16 日以邮件或书面等形式发出，会议应参加董事 6 名，实际参加 6 名。公司监事、 非董事高级管理人员及保荐代表人列席了本次会议。会议的召集、召开符合《公司法》 和《公司章程》的相关规定。 股票代码：002728 股票简称：特一药业 公告编号：2024-051 会议由董事长许丹青主持，全体董事经过审议，以现场及通讯方式进行表决，通过 了如下决议： 1、审议通过《关于审议公司 2024 年半年度报告的议案》 公司 2024 年 1-6 月的经营情况及财务状况已经公司相关部门编制完成，具体内容 详见《2024 年半年度报告》，该报告拟于 2024 年 7 月 26 日对外报出。 同时，公司本报告期的利润不派发现金红利，不送红股，不以公积金转增 ...

股票代码：002728 股票简称：特一药业 公告编号：2024-054 特一药业集团股份有限公司 关于 2024 年半年度募集资金存放与使用情况的专项报告 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集资金管理和使用的 监管要求》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》以及《深 圳证券交易所上市公司自律监管指南第 2 号——公告格式》的相关规定，特一药业集团股份有限公 司（以下简称"公司"或"本公司"）董事会编制了截至 2024 年 6 月 30 日募集资金存放与使用情况的 专项报告。 一、募集资金基本情况 （一）实际募集资金数额和资金到位时间 1、2017 年公开发行可转换公司债券募集资金 经中国证券监督管理委员会证监许可[2017]2004 号文《关于核准特一药业集团股份有限公司公 开发行可转换公司债券的批复》核准，本公司向社会公开发行面值总额 3.54 亿元的可转换公司债券， 每张面值100元，共计354万张，期限6年。公司本次发行可转债募集资金总额为人民币354,000,000.00 元，利息为 12,776.67 元，扣除承销费用、保荐费人民币 ...

编制单位：特一药业集团股份有限公司 单位：人民币万元 | | | 占用方与上市公 | 上市公司 | 2024 年期 | 2024 年半年度 占用累计发生 | 年半 2024 年度占用 | 2024 年半 年度偿还 | 2024 年半 | 占用形成 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 司的关联关系 | 核算的会计科目 | 初占用资 | 金额 | 资金的利 | 累计发生 | 年度末占用 | 原因 | 占用性质 | | | | | | 金余额 | （不含利息） | 息 | 金额 | 资金余额 | | | | | | | | | | （如有） | | | | | | 控股股东、实际控 | | | | | | | | | | | | 制人及其附属企业 | | | | | | | | | | | | 小计 | | | | | | | | | | | | 前控股股东、实际 | | | | | | | | | | | | 控制人及其附属企 | | | | | | | | | ...

股票代码：002728 股票简称：特一药业 公告编号：2024-052 特一药业集团股份有限公司 关于第五届监事会第二十二次会议决议的公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 特一药业集团股份有限公司（以下简称"公司"）第五届监事会第二十二次会议于 2024 年 7 月 25 日 08:00 在公司会议室召开，本次会议通知于 2024 年 7 月 16 日以通讯 方式发出。会议应出席监事 3 名，实际出席监事 3 名，会议的召集、召开符合《公司法》 和《公司章程》规定。 会议由公司监事会主席张名坚先生主持。与会监事审议了有关议案，一致通过以下 决议： 1、审议通过《关于审议公司 2024 年半年度报告的议案》 监事会对董事会编制的《2024 年半年度报告》进行审核后，一致认为：《2024 年半 年度报告》的编制和审议议程符合法律、法规、公司章程及内部管理制度的各项规定， 其内容和格式符合中国证监会和深圳证券交易所的各项规定，其所载资料真实、准确、 完整，不存在任何虚假记载、误导性陈述或重大遗漏。 监事会 2024 年 7 月 26 日 2、审议通过《 ...